Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal bupivicaine (bupivacaine) (Pacira BioSciences, 045423)
- Development stage
- Approved
- Lead developer
- Pacira BioSciences
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Percutaneous, Parenteral
01
Overview
Liposomal bupivacaine (EXPAREL) is an extended-release formulation of the amide-type local anesthetic bupivacaine. It utilizes the DepoFoam® multivesicular liposomal drug delivery system to encapsulate bupivacaine, allowing for a prolonged duration of action (up to 72 hours) compared to standard bupivacaine. The drug works by binding to and blocking voltage-gated sodium channels on the internal surface of nerve cell membranes, which prevents the influx of sodium ions and inhibits the initiation and conduction of nerve impulses, thereby producing local anesthesia and analgesia. Developed by Pacira BioSciences, it is FDA-approved for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block for regional analgesia.
- Brand names
- EXPAREL
- Other names
- liposomal bupivacainebupivacaine liposome injectable suspension
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)Kir (Inward-rectifier potassium channels)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on liposomal bupivicaine (bupivacaine) (Pacira BioSciences, 045423).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal bupivicaine (bupivacaine) (Pacira BioSciences, 045423).